Cytori Obtains Celution(R) Approval in Russia; To Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO…
Cytori's (NASDAQ: CYTX) Celution® One System, the next-generation device of the Company's Celution® platform, has been g…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NH…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have p…
Cytori Therapeutics (NASDAQ: CYTX) has been issued Patent No. 4653952 (the '952 patent) from the Japan Patent Office cov…
The US Patent and Trademark Office issued a new patent (US Patent No. 7,887,795; direct link to USPTO site - http://bit.…
Cytori (NASDAQ: CYTX) received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to inv…
Cytori Therapeutics (NASDAQ: CYTX) will be hosting an investor teach-in on cardiac cell therapy on Tuesday, November 16…